Effect of Anticoagulants and Storage Temperature on the Stability of Receptor Activator for Nuclear Factor-κB Ligand and Osteoprotegerin in Plasma and Serum

Clinical Chemistry

Volumn 49, Issue 12, 2003, Pages 2083-2085

  Chan, Benjamin Y Y ^a   Buckley, Katherine A ^b   Durham, Brian H ^a   Gallagher, James A ^b   Fraser, William D ^a,c  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PAGET BONE DISEASE; PLASMA; PROTEIN STABILITY; SERUM; STATISTICAL ANALYSIS; STORAGE TEMPERATURE;

ANTICOAGULANTS; BLOOD SPECIMEN COLLECTION; CARRIER PROTEINS; DRUG STABILITY; GLYCOPROTEINS; HUMANS; LIGANDS; MEMBRANE GLYCOPROTEINS; OSTEOPROTEGERIN; PLASMA; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SERUM;

EID: 0345376995     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.023747     Document Type: Article

References (14)

1. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
2. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597-602.
3. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: modulation of the expression by osteotrophic factors and cytokines. Biochem Biophys Res Commun 2000; 275:768-75.
4. Buckley KA, Fraser WD. Receptor activator for nuclear factor κB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. Ann Clin Biochem 2002;39:551-6.
5. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, et al. Immunological characterisation of circulating osteoprotegerin/ osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999;14:518-27.
6. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, et al. Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma. Proposal for a novel prognostic index. Blood 2003;102:1064-9.
7. Namba N, Manki A, Urakami T, Tanaka H, Seino Y. Serum osteoprotegerin (OPG) levels in children with Juvenile idiopathic arthritis. Bone 2003; 32(Suppl 5):119F.
8. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631-7.
9. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002;291:680-6.
10. Alvarez L, Peris P, Guanabens N, Vidal S, Ros I, Pons F, et al. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum 2003;48:824-8.
11. Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 2001;84:951-8.
12. Wuyts W, Van Wesenbeeck L, Morales-Piga A, Ralston S, Hocking L, Vanhoenacker F, et al. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone 2001;28:104-7.
13. Menaa C, Reddy SV, Kurihara N, Maeda H, Anderson D, Cundy T, et al. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest 2000;105:1833-8.
14. Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I, Hampson G. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-β oestradiol and raloxifene. J Endocrinol 2003;177:423-33.